APA (7th ed.) Citation

Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Messina, I., You, R., . . . Mrowietz, U. (2017). Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: Results from a double-blind extension study. British Journal of Dermatology, 177(4), 1033. https://doi.org/10.1111/bjd.15706

Chicago Style (17th ed.) Citation

Bissonnette, R., et al. "Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate-to-severe Psoriasis After Up to 3 Years of Treatment: Results from a Double-blind Extension Study." British Journal of Dermatology 177, no. 4 (2017): 1033. https://doi.org/10.1111/bjd.15706.

MLA (9th ed.) Citation

Bissonnette, R., et al. "Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate-to-severe Psoriasis After Up to 3 Years of Treatment: Results from a Double-blind Extension Study." British Journal of Dermatology, vol. 177, no. 4, 2017, p. 1033, https://doi.org/10.1111/bjd.15706.